gw-3965 has been researched along with Glioblastoma* in 2 studies
2 other study(ies) available for gw-3965 and Glioblastoma
| Article | Year |
|---|---|
Discovery of new LXRβ agonists as glioblastoma inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Glioblastoma; HEK293 Cells; Humans; Liver X Receptors; Machine Learning; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Oxindoles; Pyrrolidines; Spiro Compounds; Structure-Activity Relationship; Tumor Cells, Cultured | 2020 |
Activation of LXRβ inhibits tumor respiration and is synthetically lethal with Bcl-xL inhibition.
Liver-X-receptor (LXR) agonists are known to bear anti-tumor activity. However, their efficacy is limited and additional insights regarding the underlying mechanism are necessary. By performing transcriptome analysis coupled with global polar metabolite screening, we show that LXR agonists, LXR623 and GW3965, enhance synergistically the anti-proliferative effect of BH3 mimetics in solid tumor malignancies, which is predominantly mediated by cell death with features of apoptosis and is rescued by exogenous cholesterol. Extracellular flux analysis and carbon tracing experiments (U- Topics: Animals; Apoptosis; bcl-X Protein; Benzoates; Benzylamines; Carcinoma; Cell Proliferation; Cell Respiration; Disease Models, Animal; Gene Expression Profiling; Glioblastoma; Humans; Indazoles; Liver X Receptors; Melanoma; Metabolomics; Models, Theoretical; Treatment Outcome | 2019 |